文献速递痛风与晶体性关节病

痛风患者采用起始低剂量缓慢加量的别嘌醇剂量递增方案时是否需要秋水仙碱预防?一项非劣效性随机双盲安慰剂对照试验

Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial.
PubMed 文献 · Ann Rheum Dis · 2023-08-31

这项12个月双盲安慰剂对照非劣效性试验纳入200例有痛风发作史且血尿酸≥0.36 mmol/L的成人,比较秋水仙碱0.5 mg每日与安慰剂在别嘌醇起始低剂量缓慢加量方案前6个月预防痛风发作的效果。结果显示安慰剂组每月痛风发作次数为0.61(95%CI 0.47至0.74),秋水仙碱组为0.35(95%CI 0.22至0.49),平均差0.25(0.07至0.44),非劣效性p=0.92,提示安慰剂未达到非劣效。

要点

  • 安慰剂组每月痛风发作0.61次(95%CI 0.47至0.74),秋水仙碱组0.35次(95%CI 0.22至0.49),平均差0.25(0.07至0.44),非劣效性p=0.92,安慰剂未达非劣效。
  • 12个月期间两组每月痛风发作次数无差异(p=0.68),停用秋水仙碱后痛风发作增多。
  • 前6个月秋水仙碱组7例发生11次严重不良事件,安慰剂组2例发生3次。

核心结论

  • 在采用起始低剂量缓慢加量策略启动别嘌醇的前6个月,安慰剂在预防痛风发作方面未达到非劣效于秋水仙碱。
  • 停用秋水仙碱后痛风发作增多,12个月期间两组每月痛风发作次数无差异。

研究设计与样本

  • 12个月双盲、安慰剂对照非劣效性随机试验,纳入至少6个月内有一次痛风发作、符合美国风湿病学会(ACR)启动降尿酸治疗推荐且血尿酸≥0.36 mmol/L的成人。
  • 200例参与者按1:1随机分配至秋水仙碱0.5 mg每日或安慰剂,疗程前6个月。
  • 所有参与者开始别嘌醇并每月递增剂量以达到目标尿酸<0.36 mmol/L。
  • 主要疗效结局为0至6个月每月平均痛风发作次数,预设非劣效界值为0.12次/月。
  • 主要安全性结局为前6个月的不良事件。

主要发现

  • 基线至第6个月每月平均痛风发作次数:安慰剂组0.61(95%CI 0.47至0.74),秋水仙碱组0.35(95%CI 0.22至0.49),平均差0.25(0.07至0.44),非劣效性p=0.92。
  • 12个月期间两组每月平均痛风发作次数无差异(p=0.68)。
  • 前6个月严重不良事件:秋水仙碱组7例参与者共11次,安慰剂组2例参与者共3次。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine whether placebo is non-inferior to low-dose colchicine for reducing gout flares during the first 6 months of allopurinol using the 'start-low go-slow' dose approach. METHODS: A 12-month double-blind, placebo-controlled non-inferiority trial was undertaken. Adults with at least one gout flare in the preceding 6 months, fulfilling the American College of Rheumatology (ACR) recommendations for starting urate-lowering therapy and serum urate ≥0.36 mmol/L were recruited. Participants were randomised 1:1 to colchicine 0.5 mg daily or placebo for the first 6 months. All participants commenced allopurinol, increasing monthly to achieve target urate <0.36 mmol/L. The primary efficacy outcome was the mean number of gout flares/month between 0 and 6 months, with a prespecified non-inferiority margin of 0.12 gout flares/month. The primary safety outcome was adverse events over the first 6 months. RESULTS: Two hundred participants were randomised. The mean (95% CI) number of gout flares/month between baseline and month 6 was 0.61 (0.47 to 0.74) in the placebo group compared with 0.35 (0.22 to 0.49) in the colchicine group, mean difference 0.25 (0.07 to 0.44), non-inferiority p=0.92. There was no difference in the mean number of gout flares/month between randomised groups over the 12-month period (p=0.68). There were 11 serious adverse events in 7 participants receiving colchicine and 3 in 2 receiving placebo. CONCLUSIONS: Placebo is not non-inferior to colchicine in prevention of gout flares in the first 6 months of starting allopurinol using the 'start-low go-slow' strategy. After stopping colchicine, gout flares rise with no difference in the mean number of gout flares/month between groups over a 12-month period. TRIAL REGISTRATION NUMBER: ACTRN 12618001179224.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Stamp L, Horne A, Mihov B, et al. Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial. Ann Rheum Dis. 2023. PMID: 37652661. doi:10.1136/ard-2023-224731

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。